Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes (Q80455361)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 July 2007

Language	Label	Description	Also known as
English	Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes	scientific article published on 01 July 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Norbert Gattermann

8

object named as

Norbert Gattermann

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Sabine Knipp

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Barbara Hildebrand

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Andrea Kündgen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Aristoteles Giagounidis

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Guido Kobbe

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Rainer Haas

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Carlo Aul

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ulrich Germing

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

110

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

345-352

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating the prognosis of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

The outcomes and costs of acute myeloid leukemia among the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of acute myelogenous leukemia in older adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive chemotherapy in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical significance of karyotype in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical importance of cytogenetics in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors related to length of complete remission in adult acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukaemia cell drug resistance and prognostic factors in AML.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myeloid leukaemia: optimising treatment in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of myelodysplastic syndromes with 5-azacytidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22779

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22779

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559141%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80455361&oldid=2005262922"